Here's What Will Fuel Inogen's (INGN) Future Growth

Jacob Fund is a mutual fund company, released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The latest quarter showed continued market recovery, with major equity indexes reaching new all-time highs. After uncertainties regarding trade policy, finalized tariffs had a limited economic impact, stabilizing the market and refocusing investors on fundamentals. The fund anticipates a new productivity cycle that will enhance profit margins and earnings growth by keeping labor markets subdued. In addition, the fund will remain focused on companies poised for earnings growth and improved valuation multiples in expectation that asset prices could continue to rise in the near-term. Additionally, you can review the fund’s top 5 holdings to see its best picks for 2025.

In its third-quarter 2025 investor letter, Jacob Fund highlighted stocks such as Inogen, Inc. (NASDAQ:INGN). Inogen, Inc. (NASDAQ:INGN) is a medical device company that develops respiratory health products. The one-month return of Inogen, Inc. (NASDAQ:INGN) was -1.14%, and its shares lost 27.02% of their value over the last 52 weeks.  On December 05, 2025, Inogen, Inc. (NASDAQ:INGN) stock closed at $6.94 per share, with a market capitalization of $188.41 million.

Jacob Fund stated the following regarding Inogen, Inc. (NASDAQ:INGN) in its third quarter 2025 investor letter:

"The Jacob Discovery Fund added three new positions in the quarter, Inogen, Inc. (NASDAQ:INGN), Omeros and Bed Bath & Beyond. Inogen develops portable oxygen concentrators for patients with chronic respiratory conditions. The company has struggled through years of mismanagement and share losses, as lower-priced, often foreign, competitors flooded the markets. However, the business has stabilized lately and Inogen retains a dominant market share and leading brand, which sustains a price premium. New management has done an excellent job guiding the company over the past couple of years, improving profitability and reaccelerating innovation in a market that should have years and years of secular growth ahead due to the country’s aging population."

Inogen, Inc. (NASDAQ:INGN) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held Inogen, Inc. (NASDAQ:INGN) at the end of the third quarter, which was 20 in the previous quarter. While we acknowledge the potential of Inogen, Inc. (NASDAQ:INGN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.